Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to $2.7 million.

  • Capricor Therapeutics' Accounts Payables fell 5836.37% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 5836.37%. This contributed to the annual value of $3.3 million for FY2024, which is 4746.26% down from last year.
  • Capricor Therapeutics' Accounts Payables amounted to $2.7 million in Q3 2025, which was down 5836.37% from $4.8 million recorded in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' Accounts Payables peaked at $6.8 million during Q3 2023, and registered a low of $2.7 million during Q3 2025.
  • For the 5-year period, Capricor Therapeutics' Accounts Payables averaged around $4.6 million, with its median value being $4.8 million (2025).
  • Per our database at Business Quant, Capricor Therapeutics' Accounts Payables surged by 16762.98% in 2021 and then crashed by 5836.37% in 2025.
  • Over the past 5 years, Capricor Therapeutics' Accounts Payables (Quarter) stood at $3.1 million in 2021, then skyrocketed by 55.14% to $4.8 million in 2022, then grew by 29.28% to $6.3 million in 2023, then crashed by 47.46% to $3.3 million in 2024, then decreased by 17.18% to $2.7 million in 2025.
  • Its Accounts Payables stands at $2.7 million for Q3 2025, versus $4.8 million for Q2 2025 and $5.3 million for Q1 2025.